IPO - Nukkleus Inc.

Form Type: S-1/A

Filing Date: 2025-07-09

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025062353

Filing Summary: Nukkleus Inc. is filing an amendment to its S-1 registration statement to facilitate the proposed sale of 4,391,662 shares of common stock by certain selling stockholders, including 1,123,331 shares from pre-funded warrants, 2,499,999 shares from common warrants, and 543,332 shares directly. The registration is part of their process related to a private placement closed on December 20, 2024. The prospectus indicates that the company itself will not receive any proceeds from these sales but will bear the registration costs. Shares of Nukkleus are currently quoted on the Nasdaq Capital Market under the symbol "NUKK". The last reported closing price before the filing was $10.40 per share. Nukkleus is classified as an emerging growth company and has opted for reduced reporting obligations under the Jumpstart Our Business Startups Act. The document highlights that investing in their common stock carries significant risk and advises potential investors to consider various risk factors delineated in the filing. Nukkleus has recently shifted its business focus towards the defense sector following significant transactions, including a merger on December 22, 2023, and a controlling stake acquisition in Star 26 Capital Inc. for a 51% interest, which was amended on February 11, 2025. Furthermore, the company has undergone changes with certain agreements providing for additional capital through promissory notes and share warrants. The prospectus emphasizes the completion status and future plans tied to these financial maneuvers.

Form Type: S-1/A

Filing Date: 2025-06-18

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025055457

Filing Summary: Nukkleus Inc. is filing Amendment No. 2 to its Form S-1 registration statement with the SEC, indicating a proposed public sale occurring as soon as practicable after the effective date. The prospectus includes up to 4,391,664 shares of common stock to be offered by selling stockholders, including shares underlying pre-funded and common warrants, and previously issued shares related to settlements. Nukkleus is not selling its shares nor receiving proceeds from the selling stockholders but is responsible for registration costs. The company is identified as an emerging growth company, meaning it has chosen to adopt certain reduced disclosure requirements. The common stock is expected to start trading on the Nasdaq Capital Market under the symbol 'NUKK'. As of June 16, 2025, the closing price was $12.09 per share. The document conveys risks associated with investments in their common stock as detailed in a dedicated section of the prospectus.

Form Type: S-1/A

Filing Date: 2025-05-15

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025044147

Filing Summary: Nukkleus Inc. is amending its registration statement on Form S-1 for an initial public offering. This update comes after the company's previous updates and indicates a shift towards increased market visibility and presence through an IPO. The registration statement pertains to 4,391,665 shares of common stock expected to be sold by selling stockholders, including shares from pre-funded and common warrants, with no proceeds going to Nukkleus from these sales. The document outlines previous business operations, including blockchain technology ventures, its recent merger with Brilliant Acquisition Corporation, and strategic pivots towards the defense sector, amid historical challenges with revenue generation through previous agreements. Additionally, it covers recent financing arrangements, settlements, and risks associated with the business strategy and market volatility. Nukkleus currently trades on the Nasdaq under the symbol 'NUKK'. The closing price of its stock was reported at $16.00 before the filing date.

Form Type: S-1

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000121390025013050

Filing Summary: Nukkleus Inc. is registering 4,429,165 shares of common stock, including shares issuable upon the exercise of pre-funded warrants and common warrants. The securities will be offered by selling stockholders, who will sell shares at fixed, market, or negotiated prices. The company is not receiving proceeds from the sale of shares; however, it will receive proceeds from any cash exercised warrants. The document also outlines the structure and purpose of the company, following a business combination completed on December 22, 2023, and aims to provide blockchain-enabled financial technology solutions. The business focus has shifted to defense technology solutions with recent acquisitions and partnerships. Risk factors associated with investing are highlighted, and previous transactions related to debt restructuring and changes in stock structure, including a recent reverse stock split, are detailed.